Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Suvorexant Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

REPOSE Study: Reducing Delirium by Enhancing Postoperative Sleep With Suvorexant

NCT05733286
View directory record Official record
Conditions
Delirium in Old Age
Interventions
Suvorexant 20 mg, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

NCT03034018
View directory record Official record
Conditions
Insomnia
Interventions
suvorexant, placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 11, 2026, 4:51 PM EDT
Not listed Phase 4 Interventional

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

NCT02669030
View directory record Official record
Conditions
Depression, Major Depressive Disorder, MDD, Insomnia
Interventions
suvorexant, Placebo
Drug
Lead sponsor
Institute for Advanced Medical Research, Alpharetta, GA
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Atlanta, Georgia • Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant on Post-operative Sleep Disturbance

NCT05823844
View directory record Official record
Conditions
Postoperative Insomnia, Postoperative Delirium
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional

Evaluation of Suvorexant for Reduction of Brain Reactivity in Patients With Cannabis Use Disorder (Pilot Study)

NCT06584942
View directory record Official record
Conditions
Cue-reactivity, Cannabis Use Disorder, Functional MRI, Orexin Antagonist
Interventions
Suvorexant
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Not listed Phase 4 Interventional

Impact of Suvorexant on Sympathetic Nerve Activity and Baroreflex Function in Chronic Insomnia

NCT03768713
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Suvorexant to Reduce Symptoms of Nicotine Use

NCT04234997
View directory record Official record
Conditions
Smoking Cessation
Interventions
Suvorexant 20 mg, Suvorexant 0mg
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 11, 2026, 4:51 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

NCT06484075
View directory record Official record
Conditions
Healthy Volunteers, Alcohol Use Disorder (AUD)
Interventions
Placebo, Suvorexant
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

NCT03818581
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insomnia, Sleep Disorder, Inflammation
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of Suvorexant for Sleep in Children With Autism

NCT05546554
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

NCT05908526
View directory record Official record
Conditions
Insomnia
Interventions
Baseline surveys, Cognitive testing and EMAs, Actiwatch, suvorexant (or placebo), Placebo
Behavioral · Device · Drug + 1 more
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial

NCT03412591
View directory record Official record
Conditions
Sleep Disturbance, Craving, Cortisol; Hypersecretion
Interventions
Suvorexant 20 mg
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
21 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Wernersville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Terminated Phase 2 Interventional Results available

The Effects of Suvorexant on Sleep, Stress, and Cue-reactivity in Methamphetamine Use Disorder

NCT05711862
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
suvorexant (SUVO), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study of Suvorexant for Insomnia in Parkinson Disease

NCT02729714
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Burdick, Daniel, M.D.
Individual
Eligibility
30 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Recruiting Phase 3 Interventional

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)

NCT06655883
View directory record Official record
Conditions
Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Garden Grove, California • New Haven, Connecticut • Bradenton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia

NCT04706091
View directory record Official record
Conditions
Restless Legs Syndrome, Insomnia, Sleep Disorder
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers

NCT02491788
View directory record Official record
Conditions
Sleep Disorder, Shift-Work
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
20 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Suvorexant for Opioid/Stimulant Co-use

NCT05546515
View directory record Official record
Conditions
Opioid Use Disorder, Stimulant Use Disorder
Interventions
Suvorexant (dual orexin receptor antagonist), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 11, 2026, 4:51 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

NCT04273776
View directory record Official record
Conditions
Performance Enhancing Product Use
Interventions
Suvorexant 10 mg, Zolpidem, Placebos
Drug
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Federal
Eligibility
18 Years to 39 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

NCT03110315
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue, Insomnia
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Theodore R. Brown, MD MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Kirkland, Washington
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 11, 2026, 4:51 PM EDT
Terminated Phase 4 Interventional Results available

Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors

NCT06162663
View directory record Official record
Conditions
Breast Cancer, Insomnia
Interventions
Suvorexant Tablets, Placebo Control
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

NCT02527564
View directory record Official record
Conditions
Insomnia, Bipolar Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Suvorexant Versus Placebo

NCT04229095
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Suvorexant 20 mg, Placebo oral tablet
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 11, 2026, 4:51 PM EDT
Completed Early Phase 1 Interventional Results available

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

NCT05656534
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Suvorexant, Placebo
Drug · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 11, 2026, 4:51 PM EDT